NCT02230306View on ClinicalTrials.gov

Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Active Melanoma Brain Metastases
Interventions
DRUG

Cobimetinib

60mg once a day; will be taken on days 1-21 of each 28 day treatment cycle; will be taken in combination with Vemurafenib;

DRUG

Vemurafenib

960mg twice a day; 28 day treatment cycle; will be taken in combination with Cobimetinib;

Trial Locations (6)

10016

Anna Pavlick, MD, New York

10065

Memorial Sloan Kettering Cancer Center, New York

15232

UPMC Hillman Cancer Center, Pittsburgh

19104

Ravi Amaravadi, MD, Philadelphia

52242

Mohammed Milhem, MD, Iowa City

06510

Harriet Kluger, New Haven

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Melissa Burgess, MD

OTHER

NCT02230306 - Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases | Biotech Hunter | Biotech Hunter